Anne Ward
Primary Care · Alabaster, ALNPI 1952858938
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 104 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,538 and has fallen 51.8% since, to $741 in 2025.
Across 104 payments — averaging $36.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acadia Pharmaceuticals Inc$534
- Alnylam Pharmaceuticals Inc.$330
- Amgen$296
- Scpharmaceuticals Inc.$270
- Pfizer$256
- E.r. Squibb & Sons, L.L.C.$227
- plus $2K from 20 others
What the payments were for
- Food & beverage$3,816100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acadia Pharmaceuticals Inc | 8 | $534 |
| Alnylam Pharmaceuticals Inc. | 8 | $330 |
| Amgen | 13 | $296 |
| Scpharmaceuticals Inc. | 4 | $270 |
| Pfizer | 16 | $256 |
| E.r. Squibb & Sons, L.L.C. | 6 | $227 |
| AstraZeneca(2 entities) | 5 | $225 |
| Merck | 7 | $181 |
| Urovant Sciences Inc | 6 | $176 |
| Abbott | 2 | $160 |
| Regeneron Healthcare Solutions, Inc. | 2 | $146 |
| Silk Road Medical, Inc. | 1 | $139 |
| Teva Pharmaceuticals USA, Inc. | 1 | $122 |
| Eisai Inc. | 1 | $121 |
| Edwards Lifesciences | 1 | $119 |
| Novartis | 6 | $109 |
| Idorsia Pharmaceuticals US Inc | 1 | $96 |
| Johnson & Johnson | 4 | $84 |
| Esperion Therapeutics, Inc. | 4 | $68 |
| Bridgebio Pharma, Inc. | 2 | $33 |
| Sun Pharmaceutical Industries Inc. | 1 | $30 |
| Novo Nordisk | 1 | $25 |
| Boehringer Ingelheim | 1 | $21 |
| Lilly USA, LLC | 1 | $16 |
| Cvrx, Inc. | 1 | $16 |
| Bayer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,816 in reported general payments places this provider in the 85th percentile of 159 primary care providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 89 | $52,593 |
| EliquisApixaban | 49 | $41,156 |
| EntrestoSacubitril/Valsartan | 52 | $40,623 |
| OzempicSemaglutide | 29 | $34,977 |
| Repatha SureclickEvolocumab | 44 | $33,221 |
| XareltoRivaroxaban | 20 | $28,661 |
| Ranolazine ErRanolazine | 55 | $4,109 |
| BrilintaTicagrelor | 12 | $3,264 |
| Metoprolol Succinate | 163 | $2,089 |
| Olmesartan Medoxomil | 65 | $1,632 |
| Losartan Potassium | 83 | $1,450 |
| Amiodarone Hcl | 24 | $1,277 |
| Rosuvastatin Calcium | 83 | $1,114 |
| Amlodipine Besylate | 169 | $1,108 |
| Atorvastatin Calcium | 72 | $1,054 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta | $225 | $55,857101 claims |
| PfizerEliquis | $256 | $41,15649 claims |
| NovartisEntresto | $109 | $40,62352 claims |
| Novo NordiskOzempic | $25 | $34,97729 claims |
| Johnson & JohnsonXarelto | $84 | $28,66120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 159 primary care providers in Alabama.
Other primary care in Alabaster
- Keith MatthewsOpelika$20K
- Troy HendersonFultondale$18K
- April TateDothan$16K
- Brandy McGrawMobile$14K
- Cleo ValdezHuntsville$14K
- Larissa RobinsonJasper$11K
- Jamie GhrigsbyMoulton$9K
- Josh WarrenBirmingham$9K
- Amber NelsonHoover$9K
- Valerie ZiemanFoley$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.